| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* The Diabetes Center, University of California, San Francisco, CA 94143; and
University of Chicago, Chicago, IL 60637
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
mAbs elicit partial TCR signaling
that leads to T cell unresponsiveness and tolerance in vivo. In this
study, the membrane-proximal events that promote T cell inactivation by
FcR nonbinding anti-CD3 mAbs were examined. In the context of FcR
nonbinding anti-CD3, TCR complexes did not aggregate and failed to
translocate into glycolipid-enriched membrane microdomains.
Furthermore, FcR nonbinding anti-CD3 mAbs induced tyrosine
phosphorylation of the Fyn substrate Cbl, but not the ZAP-70 substrate
linker for activation of T cells. Overexpression of Fyn, but not
Lck, restored the mitogenicity of FcR nonbinding anti-CD3 in
primary T cells. Taken together, these results suggest that Fyn
mediates the partial signaling induced by TCR
antagonists. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In vitro, bivalent, FcR nonbinding forms of anti-CD3 mAbs fail to promote TCR aggregation or activate naive and primary cells. The altered anti-CD3 mAbs induce unresponsiveness of proinflammatory Th1 cells and deviation of undifferentiated T cells toward an IL-4-producing Th2 phenotype (1, 2, 3). Moreover, in vivo, FcR nonbinding anti-CD3 therapy prolongs graft survival and effectively blocks autoimmunity in murine models (4, 5). Additionally, in a recent clinical trial, humanized forms of FcR nonbinding anti-CD3 mAbs have shown promise in treating transplant rejection without eliciting systemic cytokine release and first dose toxicity often observed with conventional FcR-binding Abs (6). Thus, FcR nonbinding anti-CD3 mAbs not only are a useful reagent in studying T cell activation, anergy induction, and differentiation, but are superior immunosuppressive drugs that have potential in treating autoimmune diseases and transplant rejection.
One of the earliest signaling events induced after multivalent
cross-linking of the TCR/CD3 complex by Ag or anti-CD3 mAbs is the
triggering of a signaling cascade resulting in the phosphorylation of
the CD3, -
, -
and -
chains and the recruitment and
activation of cytoplasmic signaling molecules such as tyrosine
kinase -associated protein 70 kDa (ZAP-70).3
These membrane-proximal changes lead to an increase in
intracellular calcium, activation of mitogen-activated protein kinase
cascades, and transcriptional activation of proteins essential for
cellular expansion (7). Previous studies have shown that
the treatment of cells with FcR nonbinding anti-CD3 mAbs results in
a partial TCR signaling pattern similar to that observed in T cells
activated with altered peptide ligands (APL) (1). The
partial signaling pattern was characterized by incomplete
phosphorylation of TCR , recruitment of ZAP-70 without its
subsequent activation by phosphorylation, attenuated intracellular
calcium response, and lack of mitogen-activated protein kinase
activation.
Lck and Fyn are the two most abundantly expressed Src family kinases in
T cells and share a high degree of sequence homology (8, 9). Both kinases can mediate phosphorylation of TCR/CD3 subunits
and ZAP-70 when expressed in heterologous systems. Therefore, it is
widely accepted that the two kinases provide critical functions in
TCR-mediated signal transduction. Both Lck and Fyn are enriched within
the glycolipid-enriched membrane microdomains
(GEMs). The GEMs have been reported to be
integral to TCR signal transduction (10, 11, 12, 13). Upon T cell
activation, TCR/CD3, ZAP-70, SLP-76, and phospholipase C1 are
found in the GEMs in their highly phosphorylated, active forms. The
contribution of GEMs to T cell activation is further supported by the
observation that chemical disruption of GEMs resulted in a block of
TCR-induced calcium influx. Thus, the outcome of TCR-mediated signal
transduction most likely depends on the spatial relationship of the
TCR/CD3 complex with the GEMs and Src family kinases. However, the
functions of Lck and Fyn are distinct. Lck-deficient mice display a
profound defect in thymocyte development, which leads to almost
complete absence of peripheral T cells (14), whereas
Fyn-deficient mice have a relatively normal peripheral T cell
compartment despite an early signaling defect in their immature
thymocytes (15, 16). Additionally, the two kinases
localize to distinct subcellular compartments. Lck is found mostly at
the plasma membrane, and Fyn is associated with microtubules and the
cytoplasmic membrane (17). Finally, Lck associates with
coreceptors CD4 or CD8 (18, 19, 20) and is recruited to the
TCR/CD3 complex after T cell activation. In contrast, a small fraction
of Fyn is constitutively associated with the TCR/CD3 complex in resting
T cells (21, 22).
In this study, we examined the effects of bivalent anti-CD3 mAb-mediated TCR signal transduction, GEM formation, and the activation of Lck and Fyn. The results demonstrate that FcR nonbinding anti-CD3 mAbs fail to maximally activate Fyn and Lck or to induce the translocation of the TCR/CD3 complex into the GEMs. However, tyrosine phosphorylation of an in vivo Fyn substrate, Cbl, is induced by FcR nonbinding anti-CD3, suggesting that Fyn is responsible for the partial signal transduction induced by FcR nonbinding anti-CD3 mAbs. In support of this hypothesis, overexpression of Fyn but not Lck reconstituted proliferation of primary T cells to FcR nonbinding anti-CD3. Based on these findings, we propose that TCR antagonists induce a tolerogenic signal as a consequence of Fyn-dependent partial phosphorylation of the TCR/CD3 complex in the absence of recruitment into the kinase-rich GEMs.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Six- to 8-wk-old BALB/c and C57BL/6 mice were purchased from Frederick Cancer Research Institute Laboratories (Frederick, MD) and maintained at the University of Chicago (Chicago, IL) and the University of California (San Francisco, CA). Fyn-deficient mice backcrossed four generations to C57BL/6 were provided by Dr. A. DeFranco at the University of California, San Francisco.
Reagents
Abs used in this study were as follows: anti-CD3 (145-2C11),
goat anti-mouse-IgG3 (Sigma-Aldrich, St. Louis, MO), goat
anti-hamster IgG (Cappel, West Chester, PA), and anti-CD28
(PV-1; Dr. C. June, University of Pennsylvania, Philadelphia, PA). The
FcR nonbinding anti-CD3-fos
F(ab')2 and the anti-CD3-fos
x anti-CD4-jun bispecific
F(ab'-Zipper)2 Ab were developed and provided by
Dr. J. Tso (Protein Design Laboratories, Fremont, CA) (1).
Abs for Western blots included anti-phosphotyrosine (4G10; Upstate
Biotechnology, Lake Placid, NY), anti-Cbl (C-15; Santa Cruz
Biotechnology, Santa Cruz, CA), anti-linker for activation of T
cells (LAT) (Dr. L. E. Samelson, National Institutes of Health,
Bethesda, MD), anti-Fyn (Fyn3; Santa Cruz Biotechnology),
anti-Lck (Upstate Biotechnology), rabbit anti-mouse CD3 (a
gift from Dr. E. Palmer, Basel Institute of Immunology, Basel,
Switzerland), mouse anti-enhanced green fluorescent protein (eGFP)
mAb (clone F56-6A1.2.6), anti-TCR (H146), and
HRP-conjugated cholera toxin 
subunit (Sigma-Aldrich).
Wild-type chicken OVA peptide 323–339 (ISQAVHAAHAEINEAGR) was
synthesized at the University of Chicago peptide synthesis facility.
The antagonist peptide H331A, which has a single alanine substitution
at position 331 (23), was synthesized at the Molecular
Genetics Instrumentation Facility (Athens, GA).
T cell stimulation for biochemical analysis
Naive or primary CD4+ T cells from BALB/c,
C57BL/6, or Fyn-deficient mice were used in all experiments except for
Fig. 1
, in which the OVA-reactive T cell
clone pGL10 was used. Naive CD4+ T cells were purified from
spleens and lymph nodes by depleting CD8+ T cells
and MHC class II-positive cells. Primary CD4+ T
cells were generated by stimulating CD8+ T
cell-depleted lymph node cells with plate-bound anti-CD3 (145-2C11;
1 µg/ml) and anti-CD28 (PV-1; 1 µg/ml) for 3 days. The cells
were then transferred to T-175 culture flasks with the addition of
fresh medium and 10 U/ml recombinant human IL-2. After 4 days of
expansion, cells were harvested and resuspended at 2 x
108 cells/ml for biochemical analysis. When
purified T cell populations are used, the native anti-CD3 mAb,
145-2C11, has identical functional activities as its FcR nonbinding
counterparts (Fig. 1). Therefore, purified naive and primary
CD4+ T cells were activated with anti-CD3
mAb, 145-2C11, with or without a secondary cross-linker to assess the
effect of TCR engagement with or without high order aggregation,
respectively. T cells were incubated with 145-2C11 (5 µg/ml) for
10–20 min on ice. Multivalent TCR cross-linking was accomplished by
incubating the anti-CD3-coated cells with an equal volume of
prewarmed goat anti-hamster Ab (1/200 dilution; Cappel) at 37°C
for 5 min. The reaction was terminated by the addition of five volumes
of ice-cold PBS. Controls cells were generated in the same procedure,
substituting PBS for the relevant Abs.
|
An aliquot of 2 x 108 cells was used
for each stimulation condition. The cells were activated as described
above, pelleted, and lysed with 500 µl of ice-cold lysis buffer
(final concentration: 0.2% Triton X-100, 50 mM Tris (pH 7.6), 100 mM
NaCl, 5 mM EDTA, 1 mM
Na3VO4, 10 µg/ml each
aprotinin and leupeptin, 25 µM nitrophenyl guanidinobenzoate, and 1
mM PMSF) for 30 min on ice. The lysates were disrupted with 10 strokes
of a Dounce cell homogenizer and mixed in a Beckman ultracentrifuge
tube (Beckman Coulter, Fullerton, CA) containing an equal volume
of 80% sucrose in TNE buffer (20 mM Tris (pH 8), 150 mM NaCl, 50 mM
EDTA) to form the bottom layer of 40% sucrose plus lysate mixture.
This layer was overlaid with 3 ml of 30% sucrose in TNE and 1 ml of
5% sucrose in TNE. The tube was then filled to the top with TNE
buffer. These gradients were spun for 16 h at 40,000 rpm in a
SW-40 Ti swinging bucket rotor at 4°C in a Beckman ultracentrifuge.
The gradients were harvested into ten 0.5-ml fractions from top to
bottom. The GEMs were identified by dot blot analysis of the cholera
toxin subunit as described (12). Briefly,
nitrocellulose strips, spotted with 2 µl of each fraction, were
incubated with HRP-conjugated subunit of cholera toxin (8 ng/ml)
for 2 h and then developed using SuperSignal Chemiluminescent
Substrate (Pierce, Rockford, IL) as per the manufacturer’s
instructions. The separation of GEMs from the rest of the cellular
components was confirmed by a strong cholera toxin signal in top
fractions and no signal in heavy fractions after prolonged exposure.
The individual samples were subjected to further analysis by
immunoprecipitation and Western blotting. In some experiments, the
cholera toxin-positive GEM fractions and the bottom 1-ml heavy
fractions were pooled before immunoprecipitation and Western blot
analysis.
Immunoprecipitation and Western blot
TCR distribution in GEM and heavy fractions was determined as follows. An aliquot of lysate from the GEM and heavy fractions equivalent to 40 x 106 cells was immunoprecipitated with 50 µl of 50% protein A-agarose bead slurry (Pharmacia, Peapack, NJ) precoated with 2 µg of anti-CD3 (145-2C11) for 2 h at 4°C. For analysis of tyrosine-phosphorylated proteins in GEM and heavy fractions, 20 x 106 cell equivalents of whole cell lysates were separated. The immunoprecipitates and the whole cell lysate fractions were resolved on 12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA) for Western blot analysis. Blots were developed using SuperSignal Substrate (Pierce) as described above. Bands of phosphorylated LAT, Lck, Fyn, and ZAP-70 were initially identified by Western blot with specific Abs, and subsequently by their molecular mass in some later experiments.
To assess tyrosine phosphorylation of Cbl and LAT, naive and primary T cells were stimulated and lysed as described above, except a 1% solution of the detergent Nonidet P-40 were used in the lysis buffer. Cbl or LAT was immunoprecipitated from 20 x 106 cell equivalent of cell lysates with 30 µl of protein A beads precoated with 1 µg anti-Cbl or 1 µl anti-LAT Abs. Four-fifths of each immunoprecipitate sample was resolved on 10% SDS-PAGE for Western blot analysis of tyrosine phosphorylation. The remaining one-fifth of the sample was separated on a 10% SDS-PAGE to determine the level of Cbl or LAT protein present in each sample. The blots were developed using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce), and images were captured with a Kodak Image Station 440CF (Eastman Kodak, Rochester, NY) and quantified using Kodak Digital Science 1D Image Analysis software 3.0. The level of tyrosine phosphorylation was normalized against variations in Cbl or LAT protein in each sample.
Retroviral DNA constructs
The C-terminal regulatory tyrosines in Lck and Fyn were mutated to phenylalanine to create constitutively active kinases. The constructs were subcloned into a murine Moloney leukemia virus-based retroviral vector LXIE (a gift from Dr. H. Spits, University Hospital Free University, Amsterdam, The Netherlands) (23, 24) upstream of eGFP. The cDNA encoding Lck or Fyn was separated from that of eGFP by the internal ribosomal entry site to allow simultaneous expression of the independent proteins off a bicistronic message.
Retroviral transduction of T cells
Lymph node T cells from BALB/c or DO.11.10 mice were purified through a nylon wool column, and 2 x 106 purified T cells were added to a well in a six-well plate precoated with anti-CD3 (145-2C11; 1 µg/ml) and anti-CD28 (PV-1; 1 µg/ml). One day later, 2 x 106 retroviral DNA-transfected Phoenix Eco cells (gift from Dr. Gary Nolan, Stanford University, Stanford, CA) were added to each well. These Phoenix cells were used 2 days after transfection with LXIE vector or LXIE containing Lck or Fyn. The cells were treated with 50 µg/ml mitomycin C and washed extensively before addition to the T cell cultures. The T cells and Phoenix cells were cocultured for 3 days to allow infection of the T cells. The transduced T cells were sorted using a FACStarPlus FACS based on CD4 and eGFP expression. The sorted cells were rested for 3 days in medium containing 20 U/ml IL-2 and 0.1 mg/ml gentamicin. To access the level of Lck and Fyn expression in the transduced cells, lysate from 0.5 x 106 Lck, Fyn, or vector transduced cells were separated on 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The top halves of the blots were analyzed for Lck or Fyn expression, and the bottom halves were analyzed for eGFP expression.
[methyl-3H]Thymidine incorporation
After a 3-day rest, the sorted T cells were washed and placed in 96-well U-bottom plates. Each well contained 10,000–15,000 T cells, 50,000–75,000 gamma-irradiated BALB/c splenocytes, and varying dose of Abs or peptides in a final volume of 200 µl of complete medium. During the last 8 h of a 48-h culture period, 1 µCi of [methyl-3H]thymidine was added to each well. Thymidine incorporation was assessed as previously described (2) and was used as an index of mitogenic activity.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Previous studies have shown that activation of T cells with FcR
nonbinding anti-CD3, even in the presence of APCs, results in a
proximal signaling pattern characterized by selective TCR
phosphorylation (reversal of p23:p21 ratio) followed by limited ZAP-70
and LAT phosphorylation when compared with 145-2C11-mediated
stimulation. We hypothesized that the partial activation was a
consequence of bivalent vs multivalent TCR/CD3 cross-linking. To
directly examine this, purified T cells, prepared from a T cell clone
(pGL10), were stimulated with FcR nonbinding anti-CD3, 2C11-IgG3
(Fig. 1
A), or its parental anti-CD3 counterpart,
145-2C11 (Fig. 1B), with or without secondary cross-linking
Abs. Cell lysates were prepared, followed by anti-TCR
immunoprecipitation, followed by anti-phosphotyrosine
immunoblotting. As shown in Fig. 1, both anti-CD3 reagents induced
identical phosphoprotein patterns in the absence of cross-linking
reagent, confirming the need for effective multimerization of the
TCR/CD3 complex to effectively activate the T cells.
Engagement of TCR/CD3 complex without multivalent cross-linking fails to recruit TCR into GEMs
Previous studies have shown that TCR cross-linking leads to the
translocation of the TCR/CD3 complex into the GEMs (10, 11). Moreover, after TCR triggering, the GEM-associated TCR
-chains are fully phosphorylated, migrating with an apparent
molecular mass of 23 kDa (p23) in a reducing SDS-PAGE gel. This
suggests that the reorientation of the TCR complex into the GEMs
correlates with T cell activation. We hypothesized that the partial
activation induced by FcR nonbinding anti-CD3 mAbs may be related
to an inability of the partially activated TCR complexes to translocate
into the GEMs. To test this hypothesis, we analyzed TCR distribution in
low-density GEM and heavy fractions of the cell lysates of primary
BALB/c mouse lymph node T cells activated with anti-CD3 mAb with or
without cross-linking. The amount of CD3 and tyrosine-phosphorylated
proteins in each fraction was determined by Western blot analysis of
anti-CD3 immunoprecipitates. Before activation, the CD3
chains were observed almost exclusively in the heavy fractions. In
contrast, a significant portion of CD3 translocated into the GEM
fraction upon anti-CD3 multivalent cross-linking (Fig. 2A). In fact, phosphorylated
CD3 protein was found exclusively in the GEM fraction. Furthermore,
the TCR -chains in the GEMs were also enriched for the fully
phosphorylated p23 form (Fig. 2B, lower panel). A
phosphotyrosine blot of whole cell lysate fractions of multivalent
anti-CD3 activated T cells showed increased tyrosine
phosphorylation of many proteins, most notably proteins at 36 and 70
kDa, and higher than 100 kDa. The 36- and 70-kDa bands represent LAT
and ZAP-70, respectively (Fig. 2C). A significant fraction
of these proteins were observed in the lysate fractions containing the
GEMs. This result is consistent with previous observations suggesting
that GEMs are the cell signaling hot spots. By comparison, when cells
were incubated with the bivalent anti-CD3 mAb, the majority of the
CD3 protein remained in the heavy fraction (Fig. 2A).
Moreover, although an increase in the phosphorylation of the CD3 and
p21 was observed, all the CD3 and p21 protein was observed
in the heavy fractions (Fig. 2B, middle panel).
Furthermore, no p23 or other proteins were detected in either the
GEM or heavy fractions. Collectively, these results suggest that the
partial signaling induced by bivalent anti-CD3 engagement occurred
outside GEMs.
|
Because Src family kinases, including Lck and Fyn, have
been shown to be critical for robust T cell activation, we investigated
their activity following partial TCR signaling by analyzing tyrosine
phosphorylation of substrates specific to each kinase. Previous studies
have shown that Fyn phosphorylates Cbl during T cell activation
(25, 26, 27, 28). Therefore, we examined the effect of bivalent vs
multivalent engagement of TCR/CD3 complex by anti-CD3 Abs on Cbl
activation. As seen in Fig. 3A, incubation of T cells with
bivalent anti-CD3 mAbs induced a marked increase of tyrosine
phosphorylation of Cbl (Fig. 3, A and B). In
contrast, tyrosine phosphorylation of LAT, which is downstream of the
Lck-ZAP-70 pathway, is only observed in cells activated by multivalent
cross-linking of the TCR/CD3 complex (Fig. 3, C and
D). The level of induction of Cbl phosphorylation by
bivalent anti-CD3 varied in repeated experiments, due to
differences in detection sensitivity and responsiveness of the cells
used in each experiment. Nonetheless, in every experiment, Cbl
phosphorylation was increased only an additional 2- to 3-fold upon
multivalent cross-linking, demonstrating that bivalent anti-CD3 was
quite effective at activating Cbl phosphorylation. Moreover,
Fyn-deficient T cells did not show any increase in Cbl phosphorylation
after bivalent anti-CD3 treatment (Fig. 3, A and
B), suggesting that partial activation of Cbl
phosphorylation in wild-type T cells is mediated by Fyn. It is notable
that Fyn-deficient cells also showed reduction in LAT phosphorylation
upon TCR cross-linking. Together, these results are consistent with the
hypothesis that bivalent engagement of the TCR/CD3 complex induces a
partial signal through Fyn.
|
To further delineate the contribution of Fyn and Lck to T cell
activation by FcR nonbinding anti-CD3 mAbs, we examined the
functional effect of overexpressing constitutively active Lck or Fyn in
primary CD4+ T cells. Primary lymph node T cells
were transduced with a retroviral vector encoding a constitutively
active form of Lck or Fyn, which have their C-terminal regulatory
tyrosine residue mutated to phenylalanine. The retroviral vector also
encoded a gene for eGFP, which was separated from the genes of interest
(e.g., Lck or Fyn) by an internal ribosomal entry site. The
simultaneous expression of the genes of interest and eGFP allowed
tracking and separation of transduced T cells by FACS (Fig. 4A). Overexpression of Lck or
Fyn in transduced cells was confirmed by Western blot analysis, where
cells transduced with Lck or Fyn showed a comparable 50–100% increase
of Lck or Fyn expression when compared with the vector-transduced cells
(Fig. 4B).
|
A), indicating
that both of the overexpressed proteins were functionally active. In
contrast, only the overexpression of Fyn, but not Lck, partially
restored T cell proliferation to FcR nonbinding bivalent anti-CD3
(2C11-fos) in a dose-dependent manner (Fig. 5B).
Similar results were observed when another form of FcR nonbinding
anti-CD3, 2C11-IgG3, was used in the assay (Ref. 1 and
data not shown). Overexpression of wild-type Fyn (50–100%) resulted
in proliferation of the transduced T cells to FcR nonbinding
anti-CD3, demonstrating that the increase in Fyn expression level,
not its constitutive activation state, was critical for overcoming the
signaling defect (data not shown). Taken together, these results
suggest that bivalent anti-CD3 can preferentially activate Fyn, but
the level of Fyn in normal cells is a limiting factor in driving cell
proliferation. It is important to note that the differential effect of
Lck and Fyn was observed with only a very moderate level of
overexpression (<2-fold), suggesting that the results are physiologic
as compared with the effects of high levels of overexpression in other
systems.
|
C) T cells even in the presence of splenic APC. Recruitment
of Lck to the TCR complex using this bispecific Ab induced vigorous
proliferation in Lck-transduced cells (Fig. 5C), suggesting
that the failure of these cells to respond to FcR nonbinding
anti-CD3 mAb can be overcome by artificially recruiting Lck into
the TCR complex under the bivalent cross-linking conditions. Overexpression of Src family kinases overcomes APL-induced proliferative defect
Because FcR nonbinding anti-CD3 and altered peptide ligand
(APL) induce similar intracellular signals and cellular
functions, we were interested in determining whether Fyn overexpression
could reconstitute T cell proliferation to APL. T cells from
TCR-transgenic DO.11.10 mice were transduced with constitutively active
Lck, Fyn, or control vector as described above, and their proliferation
to wild-type OVA peptide or antagonist OVA peptide H331A
(23) was examined. Both Lck- and Fyn-overexpressing cells
exhibited enhanced proliferation to wild-type OVA peptide when compared
with cells transduced with vector alone (Fig. 6A). By comparison, Fyn- but
not Lck-overexpressing cells proliferated to OVA APL (H331A) in a
dose-dependent manner similar to the response observed with FcR
nonbinding anti-CD3 (Fig. 6B). These results demonstrate
that Fyn possesses the unique ability to overcome signaling defects
induced by TCR antagonists.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We reasoned that the difference between the ability of overexpressed
Lck and Fyn to restore T cell proliferation is likely due to their
distinct subcellular localization pattern. Because FcR nonbinding
anti-CD3 mAbs are unable to recruit and activate Lck
(1), the overexpressed Lck, as endogenous Lck, are not
targeted to the TCR complex to participate in TCR activation. In
contrast, Fyn associates with the TCR complex constitutively and is
basally active in naive and primary cells (data not shown). Therefore,
overexpression of Fyn may lead to higher TCR-Fyn association and
promotion of partial signaling by FcR nonbinding anti-CD3 to full T
cell activation. This interpretation is supported by the finding that
overexpression of Lck can restore proliferation to FcR nonbinding
anti-CD3 when Lck is recruited to the TCR complex by bispecific
anti-CD3 x anti-CD4 mAbs (Fig. 5C). In the
current study, anti-CD3-fos x
anti-CD4-jun bispecific Ab was not mitogenic for naive
and primary T cells. This differs from our previous work and most
likely reflects a higher amount of aggregated Ab present in the
preparation used in those earlier experiments (1).
Our finding of differential use of Src kinases in TCR antagonist signaling is consistent with several recent reports suggesting a unique role for Fyn in signaling by TCR antagonists. Lck-deficient JCaM1 cells reconstituted with Fyn exhibited an altered tyrosine phosphorylation pattern resembling that induced by APL or FcR nonbinding anti-CD3 (29). In addition, an antagonist cytochrome c peptide, T102G, induced activation of Fyn signal transduction in T cells from AD10 TCR-transgenic mice, which correlated with increased tyrosine phosphorylation of vav and T cell APC conjugate formation (30). However, our findings with the FcR nonbinding anti-CD3 mAb differ from those observed by Huang et al. (30) using antagonist peptide in that we did not detect significant augmentation of Fyn kinase activity after partial T cell activation. This difference may be because FcR nonbinding anti-CD3 mAbs are unable to induce TCR redistribution to form TCR caps (1), whereas antagonist peptides are able to induce loosely organized immunological synapses (31). Nonetheless, in our system, FcR nonbinding anti-CD3 did induce tyrosine phosphorylation of Cbl in a Fyn-dependent manner. In addition, the partial signals elicited by FcR nonbinding anti-CD3 were sufficient to induce anergy in Th1 cells (1) and Th2 deviation of undifferentiated Th0 cells (2), suggesting maximal activation of Fyn activity is not necessary for these cellular functions.
The basis for the inability of Fyn to mediate a complete tyrosine phosphorylation pattern remains to be determined. It has been proposed that this may be due to the distinct binding orientation of Fyn with the TCR and other molecules, thereby dictating the pattern of substrate phosphorylation (29). This hypothesis implies that Fyn, by complexing with other cytoplasmic proteins, is intrinsically deficient in its ability to induce complete tyrosine phosphorylation and initiation of T cell activation. Our finding that moderate overexpression of Fyn can restore T cell proliferation to FcR nonbinding anti-CD3 and antagonist peptides suggests that the defect is largely quantitative, perhaps due to the low stoichiometry of the Fyn-TCR complex in normal cells (21). However, because the Fyn-overexpressing T cells used in this study have normal levels of Lck, it is possible that the increase in Fyn expression restored proliferation through recruiting and activating Lck. Thus, both Fyn directly and Lck indirectly may be involved in the development of the agonist phenotype. A threshold in Fyn recruitment and activation may control Lck activation, which in turn determines the signaling pattern and functional outcome of TCR engagement (32).
The involvement of GEMs may also contribute to the quality of TCR signaling. We demonstrated that activation of both Lck and Fyn through the TCR/CD3 complex requires a high-order aggregation of the receptor complex and is associated with recruitment of the TCR into GEMs. It has been reported recently that a small pool of TCR/CD3 complexes localizes constitutively in the GEMs (33), and that the TCR inside GEMs, but not those outside GEMs, are associated with Fyn. Our preliminary results are consistent with this finding. In addition, we observed that upon engagement of bivalent anti-CD3, Fyn-TCR complexes disappeared from the GEMs and appeared in the heavy fractions (our unpublished observation). Taken together, these data suggest that the lack of TCR in GEMs in FcR nonbinding anti-CD3-treated cells may result from active exclusion.
Results from many experimental systems support the notion that partial signaling by antagonist ligand correlates with deficient Lck activation. T cell activation by agonist peptide induces the formation of a highly organized immunological synapse/supramolecular activation clusters, in which TCR/CD3 and MHC aggregate in the center with a ring of LFA-1 and ICAM-1 in the periphery (31, 34). However, partial agonist and antagonist peptides are unable to induce the organization of the immunological synapse, and the TCR and MHC are diffused loosely at the contact site. Moreover, the addition of a blocking anti-CD4 Ab to T cells before their exposure to an agonist peptide blocks the formation of an organized synapse (31). Recent studies have shown that the formation of these mature immunological synapses is preceded by transient coaggregation of TCR and CD4 at the site of T cell and APC contact and that a partial TCR agonist failed to induce such coaggregation (35). Because Lck is associated with and dependent on CD4 for its cellular localization, the efficiency of CD4 recruitment to the synapse is likely to determine the agonist or partial agonist pattern of the biochemical and functional responses (36). We demonstrated in our previous work that, in Th1 T cell clones, coligation of CD4 can restore the mitogenicity of FcR nonbinding anti-CD3 (1). Collectively, these results suggest that the partial signaling induced by APL or FcR nonbinding anti-CD3 is due to a combination of a lack of Lck recruitment and activation and the partial signals mediated by weak Fyn associations with TCR/CD3 complexes.
The results of our studies and others suggest the following model for
agonist vs antagonist signaling (Fig. 7). In resting T
cells, a small fraction of the TCR/CD3 complexes are associated with
the Fyn inside GEMs, whereas the majority of the TCR/CD3 complexes
remain outside GEMs. Upon encounter with an agonistic Ag or multivalent
cross-linked anti-CD3 Ab, more TCR/CD3 complexes become associated
with GEMs. Because a portion of Lck and Fyn localizes constitutively
inside GEMs, recruitment of the TCR into GEMs may be one mechanism by
which these kinases and the TCR are brought into close proximity to
initiate signal transduction. Enrichment of TCR-Fyn complexes in GEMs
may lead to Fyn activation by trans-phosphorylation and further
recruitment and activation of Lck. Additional engagement of the
costimulatory molecule, CD28, triggers these dispersed GEMs to coalesce
at the site of Ag/Ab binding, leading to more intense and sustained
activation of T cells (37). In contrast, upon engagement
of FcR nonbinding anti-CD3 mAb or altered peptide ligands, the
TCR/CD3 complexes move out of GEMs, which prohibits further Fyn
activation and Lck recruitment. Consequently, only the basally active
TCR-associated Fyn is available to initiate signal transduction,
resulting in a partially activated signaling pathway. We further
hypothesize that membrane compartmentalization of signaling molecules,
such as Lck and Fyn, and TCR trafficking in these compartments set the
threshold for T cell activation and control the functional outcome of
TCR engagement.
|
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Jeffrey A. Bluestone, Diabetes Center, University of California, Box 0540, 513 Parnassus Avenue, San Francisco, CA 94143-0540. E-mail address: jbluest{at}diabetes.ucsf.edu
3 Abbreviations used in this paper: ZAP-70, -associated protein of 70 kDa; APL, altered pepticle ligand; GEM, glycolipid-enriched membrane microdomain; eGFP, enhanced green fluorescent protein; LAT, linker for activation of T cells.
Received for publication August 15, 2001. Accepted for publication February 27, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544.[Abstract]
1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608.[Medline]
chain through phosphotyrosine-Src homology domain-2 interactions. J. Cell Biol. 145:377. during T cell recognition. Science 289:1349.This article has been cited by other articles:
|
|
 |
|
  K. Sugie, M.-S. Jeon, and H. M. Grey Activation of naive CD4 T cells by anti-CD3 reveals an important role for Fyn in Lck-mediated signaling PNAS, October 12, 2004; 101(41): 14859 - 14864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Z. Yu, S. D. Levin, J. Madrenas, and C. Anasetti Lck Is Required for Activation-Induced T Cell Death after TCR Ligation with Partial Agonists J. Immunol., February 1, 2004; 172(3): 1437 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chikuma, J. B. Imboden, and J. A. Bluestone Negative Regulation of T Cell Receptor-Lipid Raft Interaction by Cytotoxic T Lymphocyte-associated Antigen 4 J. Exp. Med., January 6, 2003; 197(1): 129 - 135. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
cpm, which was obtained by subtracting counts
from autoproliferation in the absence of added peptides. Results are
representative of three independent experiments.